61 related articles for article (PubMed ID: 38492861)
1. Awakening your innate power to combat AML.
Kang YA
Blood; 2024 May; 143(22):2223-2224. PubMed ID: 38814654
[No Abstract] [Full Text] [Related]
2. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
[TBL] [Abstract][Full Text] [Related]
3. STING-activating cyclic dinucleotide-manganese nanoparticles evoke robust immunity against acute myeloid leukemia.
Aikins ME; Sun X; Dobson H; Zhou X; Xu Y; Lei YL; Moon JJ
J Control Release; 2024 Apr; 368():768-779. PubMed ID: 38492861
[TBL] [Abstract][Full Text] [Related]
4. The stimulator of interferon genes (STING) agonists for treating acute myeloid leukemia (AML): current knowledge and future outlook.
Song X; Peng Y; Wang X; Chen Q; Lan X; Shi F
Clin Transl Oncol; 2023 Jun; 25(6):1545-1553. PubMed ID: 36587109
[TBL] [Abstract][Full Text] [Related]
5. Amplifying STING activation by bioinspired nanomedicine for targeted chemo- and immunotherapy of acute myeloid leukemia.
Wang X; Huang R; Wu W; Xiong J; Wen Q; Zeng Y; Chen T; Li J; Zhang C; Zhong JF; Yang S; Zhang X
Acta Biomater; 2023 Feb; 157():381-394. PubMed ID: 36375786
[TBL] [Abstract][Full Text] [Related]
6. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
[TBL] [Abstract][Full Text] [Related]
7. STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia.
Curran E; Chen X; Corrales L; Kline DE; Dubensky TW; Duttagupta P; Kortylewski M; Kline J
Cell Rep; 2016 Jun; 15(11):2357-66. PubMed ID: 27264175
[TBL] [Abstract][Full Text] [Related]
8. Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy.
Sun X; Zhang Y; Li J; Park KS; Han K; Zhou X; Xu Y; Nam J; Xu J; Shi X; Wei L; Lei YL; Moon JJ
Nat Nanotechnol; 2021 Nov; 16(11):1260-1270. PubMed ID: 34594005
[TBL] [Abstract][Full Text] [Related]
9. Catch me if you can: how AML and its niche escape immunotherapy.
Tettamanti S; Pievani A; Biondi A; Dotti G; Serafini M
Leukemia; 2022 Jan; 36(1):13-22. PubMed ID: 34302116
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia: current progress and future directions.
Kantarjian H; Kadia T; DiNardo C; Daver N; Borthakur G; Jabbour E; Garcia-Manero G; Konopleva M; Ravandi F
Blood Cancer J; 2021 Feb; 11(2):41. PubMed ID: 33619261
[TBL] [Abstract][Full Text] [Related]
11. A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment.
Nagata M; Kosaka A; Yajima Y; Yasuda S; Ohara M; Ohara K; Harabuchi S; Hayashi R; Funakoshi H; Ueda J; Kumai T; Nagato T; Oikawa K; Harabuchi Y; Esteban C; Ohkuri T; Kobayashi H
Cancer Immunol Immunother; 2021 Aug; 70(8):2301-2312. PubMed ID: 33507344
[TBL] [Abstract][Full Text] [Related]
12. A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia.
Liao D; Wang M; Liao Y; Li J; Niu T
Front Pharmacol; 2019; 10():609. PubMed ID: 31244654
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges.
Shallis RM; Wang R; Davidoff A; Ma X; Zeidan AM
Blood Rev; 2019 Jul; 36():70-87. PubMed ID: 31101526
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
